CRBP Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
36.2M
+48.9%
24.3M
+10.6%
22.0M
-10.0%
24.4M
+27.5%
19.2M
R&D
31.2M
+57.3%
19.8M
+7.7%
18.4M
-11.8%
20.9M
+37.4%
15.2M
SG&A
5.0M
+11.8%
4.5M
+26.0%
3.6M
+0.1%
3.6M
-10.3%
4.0M
Operating Income
-36190000
-48.9%
-24304000
-10.6%
-21966000
+10.0%
-24417000
-27.5%
-19152000
EBITDA
-36139000
-49.0%
-24255000
-10.7%
-21917000
+10.1%
-24367000
-27.6%
-19099000
Net Income
-35037000
-52.5%
-22969000
-11.7%
-20555000
+11.9%
-23342000
-32.2%
-17662000
EPS (Basic)
$-1.81
-47.2%
$-1.23
+0.8%
$-1.24
+34.7%
$-1.90
-31.9%
$-1.44
EPS (Diluted)
$-1.81
-47.2%
$-1.23
+0.8%
$-1.24
+34.7%
$-1.90
-31.9%
$-1.44
Shares (Diluted)
19.4M
+3.7%
18.7M
+13.2%
16.5M
+34.2%
12.3M
+0.5%
12.2M
Corbus Pharmaceuticals (CRBP) โ€” Financials